NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
Clinical Trials
17 trialsNCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04513717 2026-01-14
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT05590793 2025-09-09
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen
Phase 3 Completed
NCT01492972 2025-09-04
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Proton Collaborative Group
Phase 3 Recruiting
NCT04181203 2025-07-30
CARLHA-2
UNICANCER
Phase 3 Active not recruiting
NCT00667069 2025-06-05
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
UNICANCER
Phase 3 Completed
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT05781217 2023-11-18
URONCOR 06-24
Instituto de Investigación en OncologÃa Radioterápica - Fundación Española de OncologÃa Radioterápic
Phase 3 Recruiting
NCT05019846 2023-04-18
SPA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Recruiting
NCT00104741 2021-02-21
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
UNICANCER
Phase 3 Completed
NCT01715129 2019-12-09
DKP 3M SC
Ipsen
Phase 3 Completed
NCT00415246 2019-11-22
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
Ipsen
Phase 3 Terminated
NCT01020448 2019-01-30
Triptocare
Ipsen
Phase 3 Completed
NCT00003734 2016-07-21
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT01656161 2015-09-15
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed
NCT00751790 2014-07-25
Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer
Debiopharm International SA
Phase 3 Completed